OA10.01 Patient Preferences for Tyrosine Kinase Inhibitor Treatments for EGFR Mutation Positive Metastatic NSCLC

J. Bridges; M. De La Cruz; M. Pavilack; E. Flood; E. Janssen; N. Chehab; A. Fernandes

首页> 外文期刊>Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer >OA10.01 Patient Preferences for Tyrosine Kinase Inhibitor Treatments for EGFR Mutation Positive Metastatic NSCLC

【24h】

OA10.01 Patient Preferences for Tyrosine Kinase Inhibitor Treatments for EGFR Mutation Positive Metastatic NSCLC

机译：OA10.01患者偏偏东酪氨酸激酶抑制剂治疗EGFR突变阳性转移性NSCLC

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer》 |2018年第10期|共1页
作者
J. Bridges; M. De La Cruz; M. Pavilack; E. Flood; E. Janssen; N. Chehab; A. Fernandes;
展开▼
作者单位

Department of Biomedical Informatics The Ohio State University College of Medicine;

Icon;

Medical Affairs Oncology;

Icon;

Icon;

Medical Affairs Oncology;

Medical Affairs Oncology;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
入库时间 2022-08-19 19:53:05

相似文献

外文文献
中文文献
专利

1. 第一代EGFR酪氨酸激酶抑制剂治疗106例复合EGFR突变肺癌患者:一项单中心临床研究 [J] . Xiangyang Yu, Xuewen Zhang, Zichen Zhang, 癌症（英文版） . 2019,第010期
2. OA10.01 Patient Preferences for Tyrosine Kinase Inhibitor Treatments for EGFR Mutation Positive Metastatic NSCLC [J] . J. Bridges, M. De La Cruz, M. Pavilack, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2018,第10期

机译：OA10.01患者偏偏东酪氨酸激酶抑制剂治疗EGFR突变阳性转移性NSCLC
3. Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis. [J] . Bria E, Milella M, Cuppone F, Annals of oncology: official journal of the European Society for Medical Oncology . 2011,第10期

机译：晚期NSCLC患者的结果，这些患者具有随机分配给EGFR酪氨酸激酶抑制剂或化疗作为一线治疗的致敏EGFR突变：一项荟萃分析。
4. Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapyn as first-line treatment: a meta-analysis [J] . D. Giannarelli Annals of Oncology . 2011,第10期

机译：一线治疗的晚期NSCLC患者的结果，这些患者具有随机分配给EGFR酪氨酸激酶抑制剂或化疗的致敏性EGFR突变：荟萃分析
5. Association between tumor heterogeneity and progression-free survival in non-small cell lung cancer patients with EGFR mutations undergoing tyrosine kinase inhibitors therapy [C] . Jiangdian Song, Di Dong, Yanqi Huang, Annual International Conference of the IEEE Engineering in Medicine and Biology Society . 2016

机译：接受酪氨酸激酶抑制剂治疗的EGFR突变非小细胞肺癌患者肿瘤异质性与无进展生存的关系
6. Targeting EGFR and ErbB2 by small molecule tyrosine kinase inhibitors in human colon cancer. [D] . Zhou, Yunfei. 2005

机译：小分子酪氨酸激酶抑制剂在人结肠癌中靶向EGFR和ErbB2。
7. Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations [O] . Oscar Arrieta, Rodrigo Catalán, Silvia Guzmán-Vazquez, 2020

机译：第一和第二代EGFR酪氨酸激酶抑制剂的成本效果分析作为NSCLC患有EGFR突变的NSCLC患者的第一线治疗
8. Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis [O] . E. Bria, M. Milella, F. Cuppone, 2011

机译：高级NSCLC患者的结果，患者敏化EGFR突变随机化为EGFR酪氨酸激酶抑制剂或化学疗法作为一线治疗：META分析

OA10.01 Patient Preferences for Tyrosine Kinase Inhibitor Treatments for EGFR Mutation Positive Metastatic NSCLC

著录项

相似文献

相关主题

期刊订阅